$542.00
1.18% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

argenx SE ADR Stock price

$542.00
+55.00 11.29% 1M
+151.34 38.74% 6M
+161.57 42.47% YTD
+24.54 4.74% 1Y
+191.42 54.60% 3Y
+410.75 312.95% 5Y
+519.00 2,256.52% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-6.49 1.18%
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization $32.41b
Enterprise Value $29.34b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 18.17
P/S ratio (TTM) P/S ratio 20.07
P/B ratio (TTM) P/B ratio 7.60
Revenue growth (TTM) Revenue growth 101.07%
Revenue (TTM) Revenue $1.61b
EBIT (operating result TTM) EBIT $-396.71m
Free Cash Flow (TTM) Free Cash Flow $-146.69m
EPS (TTM) EPS $-3.50
P/E forward negative
P/S forward 16.18
EV/Sales forward 14.65
Short interest 2.95%
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a argenx SE ADR forecast:

27x Buy
84%
5x Hold
16%

Analyst Opinions

32 Analysts have issued a argenx SE ADR forecast:

Buy
84%
Hold
16%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1,615 1,615
101% 101%
100%
- Direct Costs 279 279
62% 62%
17%
1,336 1,336
112% 112%
83%
- Selling and Administrative Expenses 777 777
74% 74%
48%
- Research and Development Expense 843 843
31% 31%
52%
-285 -285
38% 38%
-18%
- Depreciation and Amortization 112 112
6% 6%
7%
EBIT (Operating Income) EBIT -397 -397
30% 30%
-25%
Net Profit -205 -205
49% 49%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Positive
Investors Business Daily
one day ago
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
Neutral
GlobeNewsWire
11 days ago
August 28, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:
Neutral
GlobeNewsWire
about one month ago
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART ® Hytrulo following June 21 st FDA approval On track to begin four additional registrational studies across efgartigimod and empasiprubart by end of 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) Regulated Information – Inside Information July 25, 2024 7:00 AM CET Amsterda...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,148
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today